Efficacy News and Research

RSS

How do symptom burden and viral kinetics differ between healthy, vaccinated adults infected with either Delta, Omicron BA.1, or BA.2?

Researchers assessed the symptom profiles present in SARS-CoV-2 Delta, Omicron BA1. and BA.2-infected patients.

12 Jul 2022

What is the long-term protection against COVID-19?

A new study describes the immunologic parameters associated with protection from COVID-19.

12 Jul 2022

Stinging nettle extract inhibits SARS-CoV-2 cell fusion

In a recent study posted to the bioRxiv* preprint server, researchers at Ghent University and KU Leuven, Belgium, demonstrated that Urtica dioica agglutinin (UDA), a monomeric lectin extracted from stinging nettle rhizomes, inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) cell to cell fusion.

12 Jul 2022

Black individuals may be more vulnerable to atherosclerosis early in life than young Hispanic adults

A unique Mount Sinai study focused on a multi-ethnic, underserved community in New York City shows that young Black adults are twice as likely to have atherosclerosis as similarly situated young Hispanic adults.

11 Jul 2022

How can we define early COVID-19 reinfections?

In a new study, researchers investigated coronavirus disease 2019 reinfections.

11 Jul 2022

How does the belief that vaccination will end the COVID-19 pandemic relate to vaccination intent?

Researchers explored the intent and belief in COVID-19 vaccination in the Netherlands.

11 Jul 2022

Study reveals sex-based differences in the clinical outcomes of COVID-19 in the US

Researchers investigated sex-based differences among COVID-19 patients in the United States.

11 Jul 2022

What is the effectiveness of the fourth dose mRNA vaccination against the Omicron variant?

Researchers evaluated the efficacy of the fourth vaccine dose against COVID-19.

11 Jul 2022

Study assesses the potential of plant secondary metabolites as potential anti-COVID-19 agents

A new study has focused on identifying plant secondary metabolites (PSM) having a higher affinity for S-RBD of SARS-CoV-2.

11 Jul 2022

New data on duration of protection afforded by natural SARS-CoV-2 infection

In a recent study posted to the medRxiv* preprint server, researchers investigated the immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) natural reinfection.

11 Jul 2022

Researchers discover the first effective drug to treat rare, genetic liver disease

Researchers at Saint Louis University's School of Medicine, in collaboration with Arrowhead Pharmaceuticals and Takeda Pharmaceuticals, report the first effective drug to treat a rare, genetic liver disease that formerly could only be treated with a liver transplant.

8 Jul 2022

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual

The NRG Oncology/Alliance clinical trial NRG-LU005, examining the addition of the immunotherapy drug atezolizumab combined with chemoradiation for patients with limited-stage small cell lung cancer (SCLC) recently reached the trial's accrual goal of 506 patients.

8 Jul 2022

New non-invasive treatment for patients suffering from treatment-resistant depression and dementia

A joint research team from the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) and City University of Hong Kong (CityU) has discovered that the electrical stimulation of the eye surface can alleviate depression-like symptoms and improve cognitive function in animal models.

8 Jul 2022

Digital mental health companies draw scrutiny and growing concerns

When Pat Paulson's son told her he was feeling anxious and depressed at college, Paulson went through her Blue Cross Blue Shield provider directory and started calling mental health therapists.

8 Jul 2022

Immunogenicity and safety of the protein-based heterodimer booster vaccine for COVID-19

Researchers compared the immunogenicity and safety of the protein-based heterodimer vaccine (PHH-1V) and BNT162b2 COVID-19 vaccines.

8 Jul 2022

The strength and breadth of antibody responses elicited by hybrid immunity to COVID-19 vaccination or infection alone

Researchers assessed neutralizing antibody responses to SARS-CoV-2 after receiving one dose of vaccine.

8 Jul 2022

Discovery of multiple new SARS-CoV-2 MPro inhibitors

In a recent study posted to the bioRxiv* preprint server, researchers performed an extensive library docking for new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) covalent and non-covalent inhibitors.

8 Jul 2022

Research assesses antigenic co-evolution of SARS-CoV-2 variants

In a recent study posted to the bioRxiv* preprint server, researchers analyzed antigenic variety across the significant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, like Omicron lineages.

8 Jul 2022

After 3 doses of COVID vaccine, most cancer patients retain detectable humoral immunity

In a recent study posted to the medRxiv* preprint server, researchers assessed the efficacy and durability of immune responses to the third dose of coronavirus disease 2019 (COVID-19) vaccines. They also assessed the efficacy of the fourth vaccine dose among severely immunocompromised patients with hematological malignancies.

7 Jul 2022

Broadness of neutralizing antibodies to sarbecoviruses depends on priming conditions

In a recent study under review at the Nature Portfolio journal and currently available on the Research Square* preprint server, researchers identified immune priming conditions that generated broadly neutralizing antibody (nAb) responses and assessed immunity post-third dose of coronavirus disease 2019 (COVID-19) vaccines such as BNT126b2 or Coronavac vaccines after two homologous doses of BNT126b2 or Coronavac vaccines.

7 Jul 2022

Efficacy News and Research

How do symptom burden and viral kinetics differ between healthy, vaccinated adults infected with either Delta, Omicron BA.1, or BA.2?

What is the long-term protection against COVID-19?

Stinging nettle extract inhibits SARS-CoV-2 cell fusion

Black individuals may be more vulnerable to atherosclerosis early in life than young Hispanic adults

How can we define early COVID-19 reinfections?

How does the belief that vaccination will end the COVID-19 pandemic relate to vaccination intent?

Study reveals sex-based differences in the clinical outcomes of COVID-19 in the US

What is the effectiveness of the fourth dose mRNA vaccination against the Omicron variant?

Study assesses the potential of plant secondary metabolites as potential anti-COVID-19 agents

New data on duration of protection afforded by natural SARS-CoV-2 infection

Researchers discover the first effective drug to treat rare, genetic liver disease

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual

New non-invasive treatment for patients suffering from treatment-resistant depression and dementia

Digital mental health companies draw scrutiny and growing concerns

Immunogenicity and safety of the protein-based heterodimer booster vaccine for COVID-19

The strength and breadth of antibody responses elicited by hybrid immunity to COVID-19 vaccination or infection alone

Discovery of multiple new SARS-CoV-2 MPro inhibitors

Research assesses antigenic co-evolution of SARS-CoV-2 variants

After 3 doses of COVID vaccine, most cancer patients retain detectable humoral immunity

Broadness of neutralizing antibodies to sarbecoviruses depends on priming conditions

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News